Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003904 | 1.00 | CSNK2A1 (0.50) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL30051933 | 0.98 | CSNK2A1 (0.52) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL17186197 | 0.83 | TAAR1 (0.67) | PNMTTAAR1 | |
| SCHEMBL1363230 | 0.82 | CSNK2A1 (0.46) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL1535743 | 0.79 | IDO1 (0.38) | PNMTTAAR1CYP3A4IDO1 | |
| SCHEMBL507688 | 0.79 | CYP4F2 (0.40) | PNMTTAAR1CYP3A4IDO1 | |
| SCHEMBL29349576 | 0.78 | PNMT (0.67) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL112200 | 0.78 | PNMT (0.67) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL28958238 | 0.78 | HRH3 (0.43) | CSNK2A1PNMTTAAR1LOXL2LOX | |
| SCHEMBL29875339 | 0.78 | HRH3 (0.43) | CSNK2A1PNMTTAAR1LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4408427-A1 | SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI SHIMMING | Merck Sharp & Dohme LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20180208580-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-26 | — | — | US | disclosed |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9951048-B1 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-11-02 | — | — | US | disclosed |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-11-02 | — | — | US | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20110251173-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-10-13 | — | — | US | disclosed |
| WO-2011121350-A1 | 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CSNK2A1 144/4885PNMT 3422/4885TAAR1 4856/4885 |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | CSNK2A1 26/4885PNMT 3571/4885TAAR1 3513/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CSNK2A1 84/4885PNMT 3421/4885TAAR1 2149/4885 |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CSNK2A1 144/4885PNMT 3422/4885TAAR1 4856/4885 |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | CSNK2A1 38/4885PNMT 2574/4885TAAR1 3490/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | CSNK2A1 1000/4885PNMT 4375/4885TAAR1 712/4885 |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | CSNK2A1 74/4885PNMT 1973/4885TAAR1 4003/4885 |
| US-20110251173-A1 | CHEMICAL COMPOUNDS | DGAT1, DGAT2, SLC5A1 | CSNK2A1 2229/4885PNMT 1252/4885TAAR1 1061/4885 |
| US-20180208580-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | CSNK2A1 26/4885PNMT 3571/4885TAAR1 3513/4885 |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | CSNK2A1 30/4885PNMT 2573/4885TAAR1 4174/4885 |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CSNK2A1 144/4885PNMT 3422/4885TAAR1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.